These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Histological examination of the lacrimal gland after experimental administration of Cladribine. Kwietniewska M; Czerny K Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):526-30. PubMed ID: 12898890 [TBL] [Abstract][Full Text] [Related]
6. Development of cladribine treatment in multiple sclerosis. Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414 [TBL] [Abstract][Full Text] [Related]
8. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients. Grieb P; Stelmasiak Z; Solski J; Nowicki J; Jakubowska B; Ryba M Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):323-7. PubMed ID: 8744654 [TBL] [Abstract][Full Text] [Related]
9. Marrow suppression produced by repeated doses of cladribine. Beutler E; Koziol JA; McMillan R; Sipe JC; Romine JS; Carrera CJ Acta Haematol; 1994; 91(1):10-5. PubMed ID: 8171930 [TBL] [Abstract][Full Text] [Related]
10. [Guidelines for drug treatment of multiple sclerosis]. Kollegger H; Vass K; Marschall I; Koch G; Deecke L Wien Klin Wochenschr; 1993; 105(16):443-52. PubMed ID: 7692677 [TBL] [Abstract][Full Text] [Related]
11. Histological examination of the extrabulbar segment of the optic nerve in experimental animals after administration of Cladribine. Kwietniewska M; Stelmasiak Z; Sekita-Krzak J; Visconti J; Czerny K Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):222-6. PubMed ID: 12898843 [TBL] [Abstract][Full Text] [Related]
12. Histological examination of the retinal ganglion layer in rabbits after experimental administration of the new immunosuppressive medicine--Cladribine. Kwietniewska M; Cybulska R; Kwietniewski P; Sekita-Krzak J; Czerny K Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):376-80. PubMed ID: 12898865 [TBL] [Abstract][Full Text] [Related]
17. HLA class II and response to interferon-beta in multiple sclerosis. Fernández O; Fernández V; Mayorga C; Guerrero M; León A; Tamayo JA; Alonso A; Romero F; Leyva L; Alonso A; Luque G; de Ramón E Acta Neurol Scand; 2005 Dec; 112(6):391-4. PubMed ID: 16281922 [TBL] [Abstract][Full Text] [Related]
18. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group. Wolters EC; Horstink MW; Roos RA; Jansen EN Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204 [No Abstract] [Full Text] [Related]
19. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Brousil JA; Roberts RJ; Schlein AL Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095 [TBL] [Abstract][Full Text] [Related]
20. Influence of the new medicine--2-CDA (Cladribine) on the ultrastructure of the extrabulbar segment of the optic nerve in rabbits of New Zealand breed. Kwietniewska M; Stelmasiak Z; Sekita-Krzak J; Visconti J; Czerny K Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):227-32. PubMed ID: 12898844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]